245 related articles for article (PubMed ID: 17662385)
1. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Au WY; Tam S; Kwong YL
Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
[No Abstract] [Full Text] [Related]
2. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
3. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
4. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
5. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
[No Abstract] [Full Text] [Related]
6. Arsenic trioxide.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
[No Abstract] [Full Text] [Related]
7. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
[No Abstract] [Full Text] [Related]
8. Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Park JA; Yun JH; Kang HJ; Shin HY; Ahn HS
Pediatr Blood Cancer; 2008 Apr; 50(4):872-4. PubMed ID: 17635008
[TBL] [Abstract][Full Text] [Related]
9. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas RA; Seftel MD; Ducas J; Seifer C
J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
[TBL] [Abstract][Full Text] [Related]
10. Oral arsenic treatment of leukemia and the risk of porphyria.
Au WY; Tam S; Fong BM; Kwong YL
Leuk Res; 2009 Apr; 33(4):598-600. PubMed ID: 18829106
[No Abstract] [Full Text] [Related]
11. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
12. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
13. Comparing two arsenic trioxide administration methods in APL therapy.
Zhou J; Meng R; Yang BF
Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
[No Abstract] [Full Text] [Related]
14. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
15. Arsenic-based therapy benefits leukemia patients.
FDA Consum; 2001; 35(1):4. PubMed ID: 11930925
[No Abstract] [Full Text] [Related]
16. Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia.
Arai A; Kitano A; Kurosu T; Yamamoto K; Miki T; Murakami N; Miura O
Am J Hematol; 2005 Jul; 79(3):247-8. PubMed ID: 15981228
[No Abstract] [Full Text] [Related]
17. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
Ueda K; Nagai S; Miyashita SI; Kaise T; Ichikawa M; Kumano K; Hangaishi A; Nannya Y; Kurokawa M
Leuk Res; 2010 Jan; 34(1):e25-6. PubMed ID: 19747729
[No Abstract] [Full Text] [Related]
18. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C
Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555
[No Abstract] [Full Text] [Related]
19. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
20. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Barbey JT; Soignet S
Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
[No Abstract] [Full Text] [Related]
[Next] [New Search]
